American Heart Journal
Volume 148, Issue 5 , Pages 747-754 , November 2004

Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

  • Sverre E. Kjeldsen, MD, PhD

      Affiliations

    • Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
    • Division of Hypertension, University of Michigan, Ann Arbor, Mich, USA
    • Corresponding Author InformationReprint requests: Sverre E. Kjeldsen, MD, PhD, Department of Cardiology, Ullevaal University Hospital, N-0407 Oslo, Norway.
    • ,
  • Stevo Julius, MD, ScD

      Affiliations

    • Division of Hypertension, University of Michigan, Ann Arbor, Mich, USA

Received 6 June 2003 ,Accepted 6 April 2004.

References 

  1. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease (a unifying hypothesis). Hypertension. 2001;37:1047–1052
  2. Gibbons G, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431–1438
  3. Collins R, Peto R, MacMahon S, et al.  Blood pressure, stroke, and coronary heart disease, part 2 (short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context). Lancet. 1990;355:827–838
  4. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. J Hypertens. 1994;12:S5–14
  5. Blood Pressure Lowering Treatment Trialists' Collaboration . Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs (results of prospectively designed overviews of randomised trials). Lancet. 2000;355:1955–1964
  6. Staessen JA, Wang J-G, Thijs L. Cardiovascular protection and blood pressure reduction (a meta-analysis). Lancet. 2001;358:1305–1315
  7. Ruilope LM, Coca A, Volpe M, et al.  ACE inhibition and cardiovascular mortality and morbidity in essential hypertension (the end of the search or a need for further investigations?). Am J Hypertens. 2002;15:367–371
  8. Hansson L, Lindholm LH, Niskanen L, et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (the Captopril Prevention Project (CAPPP) randomised trial). Lancet. 1999;353:611–616
  9. Niskanen L, Hedner T, Hansson L, et al.  Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen. Diabetes Care. 2001;24:2091–2096
  10. Hansson L, Lindholm LH, Ekbom T, et al.  Randomised trial of old and new antihypertensive drugs in elderly patients (cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study). Lancet. 1999;354:1751–1756
  11. Heart Outcomes Prevention Evaluation Study Investigators . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  12. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double-blind randomised trial. BMJ 220;324:699–702
  13. Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular outcomes in people with diabetes mellitus (results of the HOPE study and MICRO-HOPE substudy). Lancet. 2000;355:253–259
  14. Sleight P, Yusuf S, Pogue J, et al.  Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130–2132
  15. Svensson P, de Faire U, Sleight P, et al.  Comparative effects of ramipril on ambulatory and office blood pressures (a HOPE substudy). Hypertension. 2001;38:e28–32
  16. PROGRESS Collaborative Group . Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033–1041
  17. Davis BR, Cutler JA, Gordon DJ, et al.  Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342–360
  18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone (the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)). JAMA. 2000;283:1967–1975
  19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  20. Wing LMH, Reid CM, Ryan P, et al.  A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  21. Dahlöf B, Devereux RB, Kjeldsen SE, et al.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol). Lancet. 2002;359:995–1003
  22. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.  Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20:1879–1886
  23. Lindholm LH, Ibsen H, Dahlöf B, et al.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (a randomised trial against atenolol). Lancet. 2002;359:1004–1010
  24. Lithell H, Hansson L, Skoog I, et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE) (prinicipal results of a randomized double-blind intervention trial). J Hypertens. 2003;21:875–886
  25. Kilander L, Nyman H, Boberg M, et al.  Hypertension is related to cognitive impairment (a 20-year follow-up of 999 men). Hypertension. 1998;31:780–786
  26. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension (rationale and design). Blood Press. 1998;7:176–183
  27. Kjeldsen SE, Julius S, Brunner H, et al.  Characteristics of 15314 hypertensive patients at high coronary risk (the VALUE trial). Blood Press. 2001;10:83–91
  28. Julius S, Kjeldsen SE, Weber M, et al.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (the VALUE radomised trial). Lancet. 2004;363:2022–2031
  29. Weber M, Julius S, Kjeldsen SE, et al.  Blood pressure dependent and independent effects of anti-hypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049–2051
  30. Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?. Am J Cardiol. 2002;89 (Suppl 2A):27
  31. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies (challenges in improving prognosis). Am J Cardiol. 2002;89(Suppl):18

☆ Conflict of Interest Statement: Both authors were in the leadership of both the LIFE study and the VALUE trial.

PII: S0002-8703(04)00290-X

doi: 10.1016/j.ahj.2004.04.037

American Heart Journal
Volume 148, Issue 5 , Pages 747-754 , November 2004

Article Tools